Firsekibart for systemic sclerosis treatment study
Treatments studied
Part of Skin clinical trials.
This trial tests a new drug called Firsekibart for people with a specific type of systemic sclerosis (SSc) called diffuse cutaneous SSc. The goal is to see if it can safely improve skin tightness and other symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with diffuse systemic sclerosis (skin tightening on arms, legs, or trunk) for 5 years or less since your first non-Raynaud's symptom.
- Your skin score (modified Rodnan skin score) is at least 10, meaning moderate to severe skin thickening.
- You have not had any severe lung disease (your lung function tests are above 60% for FVC and 50% for DLCO).
- You are not allergic to Firsekibart or monoclonal antibodies, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This trial tests a new drug, GB261, for people with systemic sclerosis (a condition that causes thickening and hardening of the skin and can affect internal organs). It aims to see if it can help when other treatments haven't worked well enough.
This trial tests a new drug called firsekibart against an existing drug, anakinra, for people with active adult-onset Still's disease. It aims to see if firsekibart is more effective in controlling symptoms like fever, joint pain, and rash.
This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.
This trial tests if a new drug called telitacicept can safely help people with systemic sclerosis (scleroderma) who still have active disease despite standard treatments. It aims to see if the drug can slow or improve skin thickening and other symptoms.
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
Hear when a new Systemic Scleroderma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.